Quantitative Evaluation of the Impact of Relaxing Eligibility Criteria for Lung Cancer Based on Real-world Data - Trial NCT06314542
Access comprehensive clinical trial information for NCT06314542 through Pure Global AI's free database. This phase not specified trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruiting. The study focuses on Lung Cancer. Target enrollment is 50000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Timeline & Enrollment
N/A
Jan 01, 2013
Jun 30, 2026
Primary Outcome
Scale of eligibility criteria
Summary
Eligibility criteria for cancer drug trials are generally too stringent, leading to key
 issues such as low enrolment rates and lack of population diversity. In order to evaluate the
 REC of NSCLC drug trials, this study will use deep learning methods to construct a structured
 real-world database of NSCLC across dimensions, and quantitatively assess the independent
 contribution of changes in each eligibility criterion to patient numbers, clinical efficacy
 and safety.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06314542
Non-Device Trial